Bu Xiaoqing, Li Changwei, Zhang Yonghong, Xu Tan, Wang Dali, Sun Yingxian, Peng Hao, Xu Tian, Chen Chung-Shiuan, Bazzano Lydia A, Chen Jing, He Jiang
Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Cerebrovasc Dis. 2016;42(3-4):186-95. doi: 10.1159/000444722. Epub 2016 Apr 26.
Clinical trials have generally showed a neutral effect of blood pressure (BP) reduction on clinical outcomes among acute ischemic stroke patients. We conducted a prespecified subgroup analysis to assess whether disease severity modifies the effect of early antihypertensive treatment on death and disability among patients with acute ischemic stroke.
In the China Antihypertensive Trial in Acute Ischemic Stroke, 4,071 patients with acute ischemic stroke and elevated BP were randomly assigned to receive antihypertensive treatment or to discontinue all hypertension medications within 48 h of symptom onset. The primary outcome was a combination of death and major disability at 14 days or hospital discharge. In this subgroup analysis, participants were categorized into 3 groups according to their baseline NIH Stroke Scale (NIHSS) scores (0-4, 5-15, or ≥16).
At 24 h after randomization, mean systolic BP differences (95% CIs) were -8.5 (-10.0 to -7.1), -9.8 (-11.4 to -8.3), and -9.1 (-14.4 to -3.8) mm Hg between the treatment and control groups (all p values <0.001) for patients with a baseline NIHSS score of 0-4, 5-15, and ≥16, respectively. At day 7 after randomization, the corresponding mean systolic BP differences were -9.3 (-10.5 to -8.2), -9.1 (-10.3 to -7.8), and -10.1 (-15.1 to -5.1) mm Hg between the treatment and control groups (all p values <0.001). The primary outcome was not significantly different between the treatment and control groups at day 14 or hospital discharge among all NIHSS subgroups (p value for homogeneity = 0.66). ORs (95% CI) associated with treatment were 1.14 (0.87-1.49, p = 0.33), 1.04 (0.86-1.25, p = 0.70), and 0.67 (0.18-2.44, p = 0.54) for patients with a baseline NIHSS score of 0-4, 5-15, and ≥16, respectively. The composite outcome of death and major disability at 3-month follow-up did not differ between the 2 comparison groups for all NIHSS subgroups. In addition, vascular events and recurrent stroke were not significantly different between the 2 comparison groups at the 3-month follow-up visit among all NIHSS subgroups except that there was a suggestive risk reduction for recurrent stroke among those with an NIHSS score of 5-15 (OR 0.45, 95% CI 0.20-0.99, p = 0.05).
Early BP reduction with antihypertensive medications did not reduce or increase the risk of death, major disabilities, recurrent instances of stroke, and vascular events in acute ischemic stroke patients with a variety of disease severities.
临床试验总体显示,降低血压对急性缺血性脑卒中患者的临床结局呈中性影响。我们进行了一项预先设定的亚组分析,以评估疾病严重程度是否会改变早期降压治疗对急性缺血性脑卒中患者死亡和残疾的影响。
在中国急性缺血性脑卒中降压试验中,4071例急性缺血性脑卒中和血压升高的患者在症状发作后48小时内被随机分配接受降压治疗或停用所有高血压药物。主要结局是14天时或出院时的死亡和严重残疾的综合情况。在该亚组分析中,参与者根据其基线美国国立卫生研究院卒中量表(NIHSS)评分分为3组(0 - 4分、5 - 15分或≥16分)。
随机分组后24小时,基线NIHSS评分为0 - 4分、5 - 15分和≥16分的患者,治疗组与对照组之间的平均收缩压差异(95%置信区间)分别为 - 8.5(- 10.0至 - 7.1)、- 9.8(- 11.4至 - 8.3)和 - 9.1(- 14.4至 - 3.8)mmHg(所有p值<0.001)。随机分组后第7天,治疗组与对照组之间相应的平均收缩压差异分别为 - 9.3(- 10.5至 - 8.2)、- 9.1(- 10.3至 - 7.8)和 - 10.1(- 15.1至 - 5.1)mmHg(所有p值<0.001)。在所有NIHSS亚组中,治疗组与对照组在14天时或出院时的主要结局无显著差异(同质性p值 = 0.66)。基线NIHSS评分为0 - 4分、5 - 15分和≥16分的患者,与治疗相关的比值比(95%置信区间)分别为1.14(0.87 - 1.49,p = 0.33)、1.04(0.86 - 1.25,p = 0.70)和0.67(0.18 - 2.44,p = 0.54)。在所有NIHSS亚组中,3个月随访时死亡和严重残疾的复合结局在两个比较组之间无差异。此外,在所有NIHSS亚组中,3个月随访时两个比较组之间的血管事件和复发性卒中无显著差异,除了NIHSS评分为5 - 15分的患者中复发性卒中有提示性的风险降低(比值比0.45,95%置信区间0.20 - 0.99,p = 0.05)。
使用降压药物早期降低血压并未降低或增加各种疾病严重程度的急性缺血性脑卒中患者的死亡、严重残疾、复发性卒中及血管事件风险。